太龙药业(600222.SH)：继续停牌

Group 1 - The core point of the article is that Tailong Pharmaceutical (600222.SH) is actively promoting a significant matter with its controlling shareholder and negotiating transaction terms with the counterparties [1] - The company expects to remain suspended from trading until December 4, 2025, due to the need for internal approval procedures by all parties involved in the transaction [1] - An application has been made to the Shanghai Stock Exchange for the stock to continue being suspended, with an expected suspension period not exceeding three trading days [1]